Viridian Therapeutics, Inc.

NasdaqCM:VRDN Stock Report

Market Cap: US$2.5b

Viridian Therapeutics Future Growth

Future criteria checks 5/6

Viridian Therapeutics is forecast to grow earnings and revenue by 63% and 52.1% per annum respectively. EPS is expected to grow by 63.9% per annum. Return on equity is forecast to be -45.6% in 3 years.

Key information

63.0%

Earnings growth rate

63.93%

EPS growth rate

Biotechs earnings growth29.0%
Revenue growth rate52.1%
Future return on equity-45.59%
Analyst coverage

Good

Last updated07 Aug 2026

Recent future growth updates

Analysis Article • Aug 09

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Shareholders will be ecstatic, with their stake up 25% over the past week following Viridian Therapeutics, Inc. 's...

Recent updates

Analysis Article • Aug 12

Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22%

Today is shaping up negative for Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) shareholders, with the analysts delivering...
Analysis Article • Aug 09

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Shareholders will be ecstatic, with their stake up 25% over the past week following Viridian Therapeutics, Inc. 's...
Seeking Alpha • Jun 30

Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval

Summary Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results. I see significant upside potential from VRDN-008's phase 1 results and the FcRn pipeline (VRDN-006 and VRDN-008), and with the TSHR antibody offering longer-term expansion into Graves' disease. Read the full article on Seeking Alpha
Analysis Article • Jun 19

Viridian Therapeutics (VRDN) Stock Could Be 84.84% Below Fair Value After Institutional Buying

Viridian Therapeutics (VRDN) is back on investors' radar after a rise in institutional ownership and strong year over year gains in quarterly revenue and net profit, which has drawn fresh attention to the stock. See our latest analysis for Viridian Therapeutics. At a share price of $16.63, Viridian Therapeutics has seen its 7 day and 30 day share price returns of 3.04% and 4.13% contrast with a much weaker 90 day share price return, while a 1 year total shareholder return of 10.87% sits...
Analysis Article • Apr 21

Need To Know: The Consensus Just Cut Its Viridian Therapeutics, Inc. (NASDAQ:VRDN) Estimates For 2026

One thing we could say about the analysts on Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) - they aren't optimistic...
Analysis Article • Nov 22

Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) shares have been powering on, with a gain of...
Analysis Article • Nov 10

Analysts' Revenue Estimates For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Are Surging Higher

Shareholders in Viridian Therapeutics, Inc. ( NASDAQ:VRDN ) may be thrilled to learn that the analysts have just...
Analysis Article • Jul 01

Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 02

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Summary Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive and Thrive-2 trials bolster confidence, with VRDN-001 demonstrating rapid response and consistent efficacy in both active and chronic TED. Financially stable with a cash runway into 2027, Viridian is well-positioned for FDA approval, expected to be a significant catalyst for the stock. Despite Tepezza's market dominance, VRDN-001's superior diplopia resolution and chronic TED data offer potential differentiation and long-term market penetration. Read the full article on Seeking Alpha
Analysis Article • Feb 11

Is Viridian Therapeutics (NASDAQ:VRDN) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Dec 20

Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$18.7 Based On Its Intrinsic Value?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Viridian Therapeutics fair value estimate is US$14.75 Current...
Analysis Article • Nov 14

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 11

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Seeking Alpha • Sep 10

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Summary Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for THRIVE-2 study, using veligrotug for the treatment of patients with chronic thyroid eye disease, expected end of 2024. It is expected that the 7 major thyroid eye disease markets will reach $4.13 billion by 2034. VRDN-006 and VRDN-008 are two anti-FcRn drugs being developed to treat patients with autoimmune disorders. Read the full article on Seeking Alpha
Seeking Alpha • Jun 12

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Summary Viridian Therapeutics, Inc. is down year-to-date despite the company executing its clinical strategy and despite the pipeline advancing in line with the guidance management provided. THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients are the most important catalysts for the company this year. Matching Tepezza's efficacy and safety would be considered a win, but there is potential for better efficacy and safety. The phase 3 trial design for VRDN-003 addresses concerns about the company needing to conduct a phase 2 trial before going to phase 3. Anti-FcRn pipeline with VRDN-006 and VRDN-008 should get more visibility going forward with non-human primate data of VRDN-008 in 2H 2024 and phase 1 results of VRDN-006 in 2H 2025. Read the full article on Seeking Alpha
Analysis Article • May 28

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Sep 12

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Earnings and Revenue Growth Forecasts

NasdaqCM:VRDN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028585-27-13-1811
12/31/2027232-322-317-22314
12/31/202628-466-424-37714
6/30/202671-334-335-333N/A
3/31/202671-303-304-303N/A
12/31/202571-282-277-276N/A
9/30/202571-245-326-326N/A
6/30/20250-276-310-309N/A
3/31/20250-243-280-280N/A
12/31/20240-209-233-232N/A
9/30/20240-148-197-197N/A
6/30/20240-137-169-168N/A
3/31/20240-143-168-167N/A
12/31/20230-175-185-184N/A
9/30/20230-217-181-180N/A
6/30/20231-198-163-162N/A
3/31/20232-172-136-135N/A
12/31/20222-87-95-94N/A
9/30/20222-113-77-76N/A
6/30/20221-98-68-68N/A
3/31/20222-87-65-64N/A
12/31/20213-79-55-55N/A
9/30/20213-141-48-47N/A
6/30/20213-133-41-41N/A
3/31/20212-121-33-33N/A
12/31/20201-111-30-30N/A
9/30/20202-30-28-28N/A
6/30/20203-36-32-32N/A
3/31/20205-38N/A-33N/A
12/31/20194-42N/A-36N/A
9/30/20194-42N/A-36N/A
6/30/20194-40N/A-34N/A
3/31/20194-40N/A-31N/A
12/31/20188-33N/A-27N/A
9/30/20189-29N/A-26N/A
6/30/201810-26N/A-25N/A
3/31/20188-24N/A-27N/A
12/31/20174-27N/A-28N/A
9/30/20173-26N/A-24N/A
6/30/20173-24N/A-21N/A
3/31/20173-21N/A-19N/A
12/31/20163-17N/A-15N/A
9/30/20164-17N/A-14N/A
12/31/20155-16N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VRDN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.7%).

Earnings vs Market: VRDN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: VRDN is expected to become profitable in the next 3 years.

Revenue vs Market: VRDN's revenue (52.1% per year) is forecast to grow faster than the US market (13.4% per year).

High Growth Revenue: VRDN's revenue (52.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: VRDN is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 21:46
End of Day Share Price 2026/09/15 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Viridian Therapeutics, Inc. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Jason ButlerCitizens JMP Securities, LLC
Andrew PetersDeutsche Bank